v3.26.1
Segment Information - General (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Net product sales, cost of product sales and gross profit by product    
Total revenues $ 781.5 $ 794.4
Cost of sales 133.4 92.5
Gross profit (loss) 648.1 701.9
Inventory reserve 44.9 9.0
Tyvaso DPI    
Net product sales, cost of product sales and gross profit by product    
Total revenues 330.3 302.5
Cost of sales 83.2 48.1
Gross profit (loss) 247.1 254.4
Inventory reserve 39.2 5.8
Loss related to commercial supply agreement 26.8  
Nebulized Tyvaso    
Net product sales, cost of product sales and gross profit by product    
Total revenues 127.2 163.8
Cost of sales 8.6 8.5
Gross profit (loss) 118.6 155.3
Remodulin    
Net product sales, cost of product sales and gross profit by product    
Total revenues 126.6 138.2
Cost of sales 16.1 13.8
Gross profit (loss) 110.5 124.4
Orenitram    
Net product sales, cost of product sales and gross profit by product    
Total revenues 135.6 120.7
Cost of sales 7.4 8.3
Gross profit (loss) 128.2 112.4
Unituxin    
Net product sales, cost of product sales and gross profit by product    
Total revenues 53.6 58.2
Cost of sales 5.0 5.2
Gross profit (loss) 48.6 53.0
Adcirca    
Net product sales, cost of product sales and gross profit by product    
Total revenues 2.9 6.0
Cost of sales 1.0 2.6
Gross profit (loss) 1.9 3.4
Other    
Net product sales, cost of product sales and gross profit by product    
Total revenues 5.3 5.0
Cost of sales 12.1 6.0
Gross profit (loss) $ (6.8) $ (1.0)